et al., Biochem. Biophys. Res. Comm., 323:1, 8 October 2004, doi:10.1016/j.bbrc.2004.08.085 (Peer Reviewed) (In Vitro) (not included in the study count)
In vitro inhibition of severe acute respiratory syndrome coronavirus by ch loroquine
study, SARS-CoV-1, not included in the study count or percentages. IC50 of C
Q for antiviral activity (8.8) is significantly lower than cytostatic activity CC50 (261.3), selectivity index of 30. IC50 for inhibition of SARS-CoV in vitro
approximates the plasma concentrations of C
Q reached during treatment of acute malaria. C
Q may be considered for immediate use in the prevention and treatment of SARS-CoV infections.
Please send us corrections, updates, or comments: